Objectives: To evaluate the efficacy and safety of nafamostat combined with favipiravir for coronavirus disease 2019. Methods: We conducted a multicenter, randomized, single-blind, placebo-controlled parallel assignment study in hospitalized patients with mild-to-moderate coronavirus disease 2019 pneumonia. Patients were randomly assigned to receive favipiravir alone (n=24) or nafamostat with favipiravir (n=21). Outcomes included changes in the WHO Clinical Progression Scale score, time to improvement in body temperature, and improvement in oxygen saturation (SpO2). Results: There was no significant difference in changes in the Clinical Progression Scale between nafamostat with favipiravir and favipiravir alone groups (median, −0·444 vs. −0·150, respectively; least-squares mean difference, −0·294; p=0·364). Time to improvement in body temperature was significantly shorter in the combination group (5·0 days; 95% CI, 4·0–7·0) than in the favipiravir group (9·0 days; 95% CI, 7·0–18·0; p=0·009). Changes in SpO2 were greater in the combination group than that in the favipiravir group (0·526% vs. −1·304%, respectively; least-squares mean difference, 1·831; p=0·022). No serious adverse events or deaths were reported, but phlebitis occurred in 57·1% of patients in the combination group. Conclusions: Although our study showed no differences in clinical progression, earlier defervescence and recovery of SpO2 were observed in the combination group.

Fuente: International Journal of Infectious Diseases
Available online 4 January 2023